Literature DB >> 20559828

Surgical treatment of bone metastases in patients with lung cancer.

Sandra Utzschneider1, Ewa Wicherek, Patrick Weber, Gerwin Schmidt, Volkmar Jansson, Hans Roland Dürr.   

Abstract

Lung cancer is the leading cause of cancer mortality. Bone metastases are a common complication in lung cancer. The therapeutic approach and the type of surgical treatment of these lesions have not been clearly defined. Outcome and prognosis of patients with bony metastases and a variety of surgical interventions were analysed retrospectively. In 58 patients we performed 62 surgeries. The most common locations of metastases were the spine (32 patients), the proximal femur (10) and the pelvis (11). Twenty-one patients had a singular and 20 had multiple osseous lesions; 17 showed additional visceral involvement. Nine patients had a local progression of their disease and 49 a systemic progression. Patients with local progression (n = 9) had a better prognosis than the patients with systemic progression (p = 0.0083). Fracture (p = 0.0017) worsened prognosis, whereas the number of bone lesions or the presence of a visceral lesion did not. Patients with small lesions showed a better survival than patients with large lesions (p = 0.02). Ten percent of the patients died within 30 days and 78% within one year after surgery. Fracture of bone due to metastatic lung cancer worsens the prognosis whereas the number of bone lesions, the presence of a visceral lesion and the surgical approach do not.

Entities:  

Mesh:

Year:  2010        PMID: 20559828      PMCID: PMC3080497          DOI: 10.1007/s00264-010-1074-9

Source DB:  PubMed          Journal:  Int Orthop        ISSN: 0341-2695            Impact factor:   3.075


  29 in total

Review 1.  The treatment of metastases in the appendicular skeleton.

Authors:  R Capanna; D A Campanacci
Journal:  J Bone Joint Surg Br       Date:  2001-05

2.  Surgical treatment of osseous metastases in patients with renal cell carcinoma.

Authors:  H R Dürr; M Maier; M Pfahler; A Baur; H J Refior
Journal:  Clin Orthop Relat Res       Date:  1999-10       Impact factor: 4.176

3.  The surgical treatment of bony metastases of the spine and limbs.

Authors:  P Böhm; J Huber
Journal:  J Bone Joint Surg Br       Date:  2002-05

4.  The new International Staging System for Lung Cancer.

Authors:  C F Mountain
Journal:  Surg Clin North Am       Date:  1987-10       Impact factor: 2.741

5.  Surgical treatment of lung cancer with vertebral invasion.

Authors:  Kiyoshi Koizumi; Shuji Haraguchi; Tomomi Hirata; Kyoji Hirai; Iwao Mikami; Shigeki Yamagishi; Daisuke Okada; Hiroyasu Kinoshita; Yutaka Enomoto; Yuki Nakajima; Kazuo Shimizu
Journal:  Ann Thorac Cardiovasc Surg       Date:  2004-08       Impact factor: 1.520

6.  Surgical treatment of bone metastasis followed by a primary lung cancer lesion: report of a case.

Authors:  Masahiko Higashiyama; Ken Kodama; Koji Takami; Naozumi Higaki; Terumasa Yamada; Masayuki Mano; Yoshitane Tsukamoto; Nobuhito Araki; Hideki Yoshikawa
Journal:  Surg Today       Date:  2004       Impact factor: 2.549

7.  The Scandinavian Sarcoma Group Skeletal Metastasis Register. Survival after surgery for bone metastases in the pelvis and extremities.

Authors:  B H Hansen; J Keller; M Laitinen; P Berg; S Skjeldal; C Trovik; J Nilsson; A Walloe; A Kalén; R Wedin
Journal:  Acta Orthop Scand Suppl       Date:  2004-04

8.  Cancer statistics, 2009.

Authors:  Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Yongping Hao; Jiaquan Xu; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2009-05-27       Impact factor: 508.702

9.  Prognostic factors for survival in patients with inoperable lung cancer.

Authors:  K E Stanley
Journal:  J Natl Cancer Inst       Date:  1980-07       Impact factor: 13.506

10.  [Natural history and development of bone metastasis. Apropos of 429 cases].

Authors:  T Conroy; L Malissard; D Dartois; E Luporsi; J Stines; C Chardot
Journal:  Bull Cancer       Date:  1988       Impact factor: 1.276

View more
  8 in total

Review 1.  Biomaterial scaffolds for treating osteoporotic bone.

Authors:  Julie A Sterling; Scott A Guelcher
Journal:  Curr Osteoporos Rep       Date:  2014-03       Impact factor: 5.096

2.  MicroRNA-122-3p inhibits tumor cell proliferation and induces apoptosis by targeting Forkhead box O in A549 cells.

Authors:  Wen Wang; Jinsong Yang; Fenglei Yu; Wenjie Li; Li Wang; Haoyu Zou; Xia Long
Journal:  Oncol Lett       Date:  2017-12-11       Impact factor: 2.967

Review 3.  Bone metastases in non-small cell lung cancer: a narrative review.

Authors:  Brendan J Knapp; Siddhartha Devarakonda; Ramaswamy Govindan
Journal:  J Thorac Dis       Date:  2022-05       Impact factor: 3.005

4.  A long femoral stem is not always required in hip arthroplasty for patients with proximal femur metastases.

Authors:  Zhiqing Xing; Bryan S Moon; Robert L Satcher; Patrick P Lin; Valerae O Lewis
Journal:  Clin Orthop Relat Res       Date:  2013-01-30       Impact factor: 4.176

5.  A rare case of scapular metastasis from bronchogenic carcinoma with ipsilateral malignant pleural effusion.

Authors:  Anirban Das; Sabyasachi Choudhury; Sumitra Basuthakur; Angshuman Mukhopadhyay
Journal:  Lung India       Date:  2015 Jul-Aug

6.  Factors Associated with Life Expectancy in Patients with Metastatic Spine Disease from Adenocarcinoma of the Lung.

Authors:  C Rory Goodwin; Mohamed H Khattab; Eric W Sankey; Benjamin D Elder; Thomas A Kosztowski; Rachel Sarabia-Estrada; Ali Bydon; Timothy F Witham; Jean-Paul Wolinsky; Ziya L Gokaslan; Daniel M Sciubba
Journal:  Global Spine J       Date:  2015-06-05

Review 7.  The surgical management and treatment of metastatic lesions in the proximal femur: A mini review.

Authors:  Helin Feng; Jin Wang; Jianfa Xu; Wei Chen; Yingze Zhang
Journal:  Medicine (Baltimore)       Date:  2016-07       Impact factor: 1.889

Review 8.  Targeted Nanomedicine to Treat Bone Metastasis.

Authors:  Isaac M Adjei; Madison N Temples; Shannon B Brown; Blanka Sharma
Journal:  Pharmaceutics       Date:  2018-10-25       Impact factor: 6.321

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.